Literature DB >> 6976793

Uncontrolled thrombocytosis in chronic myeloproliferative disorders.

C M Kessler, H G Klein, R J Havlik.   

Abstract

A retrospective study was performed to examine the natural course of uncontrolled thrombocytosis associated with chronic myeloproliferative disorders. Thirty-eight patients with polycythaemia rubra vera (PV), myelofibrosis/myeloid metaplasia (MM), chronic myelogenous leukaemia (CML) or essential thrombocythaemia (ET) had platelet counts greater than 1000 X 10(9)/1 and were followed closely for a total of 246 patient years. Eleven of the patients experienced haemorrhagic episodes. Bleeding was twice as frequent in patients over 59 years old as in those younger and no bleeding occurred in those less than 51 years of age. There was no correlation between frequency of bleeding and extent of thrombocytosis. Bleeding events occurred concurrently with use of anti-inflammatory agents in 32% of episodes. The gastrointestinal tract was the most frequent site. Documented thrombotic events occurred in three patients, two of whom had PV with haematocrits greater than 53%. This study suggests that the thrombocytosis of myeloproliferative processes may pose a less serious threat than originally thought and that aggressive lowering of the platelet count may not be indicated in all cases.

Entities:  

Mesh:

Year:  1982        PMID: 6976793     DOI: 10.1111/j.1365-2141.1982.tb01900.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Hepatic and portal vein-thrombosis.

Authors:  B J Boughton
Journal:  BMJ       Date:  1991-01-26

2.  Familial essential thrombocythemia: clinical characteristics of 11 cases in one family.

Authors:  R J Schlemper; A P van der Maas; J C Eikenboom
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

3.  Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Hosp Physician       Date:  1999-07

4.  Cardiac Complications of Myeloproliferative Disorders.

Authors:  Muhammad Wasif Saif; Umer Khan; Bernard R Greenberg
Journal:  Resid Staff Physician       Date:  2001-07

5.  Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.

Authors:  H Ludwig; W Linkesch; H Gisslinger; E Fritz; H Sinzinger; T Radaszkiewicz; A Chott; R Flener; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.

Authors:  A Wehmeier; I Daum; H Jamin; W Schneider
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

7.  Postsplenectomy reactive thrombocytosis.

Authors:  Palwasha N Khan; Rajasree J Nair; Jairo Olivares; Leslie E Tingle; Zhiyong Li
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-01

8.  Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases.

Authors:  B R Anger; E Seifried; J Scheppach; H Heimpel
Journal:  Klin Wochenschr       Date:  1989-08-17

9.  Hemothorax following Uncomplicated Endoscopic Variceal Sclerotherapy and Ligation for Esophageal Varices.

Authors:  Tomoko Ochiai; Yukiomi Nakade; Rena Kitano; Shunsuke Kato; Kazumasa Sakamoto; Tadahisa Inoue; Yuji Kobayashi; Norimitsu Ishii; Tomohiko Ohashi; Yoshio Sumida; Kiyoaki Ito; Haruhisa Nakao; Chihiro Furuta; Motoki Yano; Masashi Yoneda
Journal:  Case Rep Gastroenterol       Date:  2017-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.